|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Burden of Clostridium difficile infection between 2010 and 2013:Trends and outcomes from an academic center in Eastern Europe显示文摘AIM:To analyze the incidence and possible risk factors in hospitalized patients treated with Clostridium difficile infection(CDI).METHODS:A total of 11751 patients were admitted to our clinic between 1 January 2010 and 1 May2013.Two hundred and forty-seven inpatients were prospectively diagnosed with CDI.For the risk analysis a 1:3 matching was used.Data of 732 patients matched for age,sex,and inpatient care period and unit were compared to those of the CDI population.Inpatient records were collected from an electronic hospital database and comprehensively reviewed.RESULTS:Incidence of CDI was 21.0/1000 admissions(2.1%of all-cause hospitalizations and 4.45%of total inpatient days).The incidence of severe CDI was 12.6%(2.63/1000 of all-cause hospitalizations).Distribution of CDI cases was different according to the unit type,with highest incidence rates in hematology,gastroenterology and nephrology units(32.9,25 and24.6/1000 admissions,respectively) and lowest rates in 1.4%(33/2312) in endocrinology and general internal medicine(14.2 and 16.9/1000 admissions)units.Recurrence of CDI was 11.3%within 12 wk after discharge.Duration of hospital stay was longer in patients with CDI compared to controls(17.6 ± 10.8d vs 12.4 ± 7.71 d).CDI accounted for 6.3%of allinpatient deaths,and 30-d mortality rate was 21.9%(54/247 cases).Risk factors for CDI were antibiotic therapy[including third-generation cephalosporins or fluoroquinolones,odds ratio(OR) = 4.559;P < 0.001],use of proton pump inhibitors(OR = 2.082,P< 0.001),previous hospitaiization within 12 mo(OR = 3.167,P < 0.001),previous CDI(OR = 15.32;P < 0.001),while presence of diabetes mellitus was associated with a decreased risk for CDI(OR = 0.484;P< 0.001).Treatment of recurrent cases was significantly different from primary infections with more frequent use of vancomycin alone or in combination(P < 0.001),and antibiotic therapy duration was longer(P < 0.02).Severity,mortality and outcome of primary infections and relapsing cases did not significantly differ.CONCLUSION:CDI was accounted for significant burden with longer hospitaiization and adverse outcomes.Antibiotic,PPI therapy and previous hospitaiization or CDI were risk factors for CDI. | Zsuzsanna Kurti Barbara D Lovasz Michael D Mandel Zoltan Csima Petra A Golovics Bence D Csako Anna Mohas Lorant Gnczi Krisztina B Gecse Lajos S Kiss Miklos Szathmari Peter L Lakatos | 2015 | World Journal of Gastroenterology2015，21，21： | 6 |
| 2 | Disease monitoring strategies in inflammatory bowel diseases: What do we mean by “tight control”?显示文摘In recent years,there has been a critical change in treatment paradigms in inflammatory bowel diseases(IBD)triggered by the arrival of new effective treatments aiming to prevent disease progression,bowel damage and disability.The insufficiency of symptomatic disease control and the well-known discordance between symptoms and objective measures of disease activity lead to the need of reviewing conventional treatment algorithms and developing new concepts of optimal therapeutic strategy.The treat-to-target strategies,defined by the selecting therapeutic targets in inflammatory bowel disease consensus recommendation,move away from only symptomatic disease control and support targeting composite therapeutic endpoints(clinical and endoscopical remission)and timely assessment.Emerging data suggest that early therapy using a treat-to-target approach and an algorithmic therapy escalation using regular disease monitoring by clinical and biochemical markers(fecal calprotectin and C-reactive protein)leads to improved outcomes.This review aims to present the emerging strategies and supporting evidence in the current therapeutic paradigm of IBD including the concepts of“early intervention”,“treat-to-target”and“tight control”strategies.We also discuss the real-word experience and applicability of these new strategies and give an overview on the future perspectives and areas in need of further research and potential improvement regarding treatment targets and(“tight”)disease monitoring strategies. | Lorant Gonczi Talat Bessissow Peter Laszlo Lakatos | 2019 | World Journal of Gastroenterology2019，25，41： | 4 |
| 3 | Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases显示文摘The past decade has brought substantial advances in the management of inflammatory bowel diseases(IBD). The introduction of tumor necrosis factor(TNF) antagonists, evidence for the value of combination therapy, the recog-nition of targeting lymphocyte trafficking and activation as a viable treatment, and the need for early treatment of high-risk patients are all fundamental concepts for current modern IBD treatment algorithms. In this article, authors review the existing data on approved biologicals and small molecules as well as provide insight on the current positioning of approved therapies. Patient stratification for the selection of specific therapies, therapeutic targets and patient monitoring will be discussed as well. The thera-peutic armamentarium for IBD is expanding as novel and more targeted therapies become available. In the absence of comparative trials, positioning these agents is becoming difficult. Emerging concepts for the future will include an emphasis on the development of algorithms which will facilitate a greater understanding of the positioning of novel biological drugs and small molecules in order to best tailor therapy to the patient. In the interim, anti-TNF therapy remains an important component of IBD therapy with the most real-life evidence and should be considered as first-line therapy in patients with complicated Crohn's disease and in acute-severe ulcerative colitis. The safety and efficacy of these ‘older' anti-TNF therapies can be optimized by adhering to therapeutic algorithms which combine clinical and objective markers of disease severityand response to therapy. | Jason Reinglas Lorant Gonczi Zsuzsanna Kurt Talat Bessissow Peter L Lakatos | 2018 | World Journal of Gastroenterology2018，24，32： | 3 |
| 4 | Quality of care in inflammatory bowel diseases: What is the best way to better outcomes?显示文摘Inflammatory bowel disease(IBD) is a lifelong, progres-sive disease that has disabling impacts on patient's lives. Given the complex nature of the diagnosis of IBD and its management there is consequently a large economic burden seen across all health care systems. Quality in-dicators(QI) have been created to assess the different fa?ades of disease management including structure, process and outcome components. Their development serves to provide a means to target and measure quality of care(Qo C). Multiple different QI sets have been published in IBD, but all serve the same purpose of trying to achieve a standard of care that can be attained on a national and international level, since there is still a major variation in clinical practice. There have been many recent innovative developments that aim to improve Qo C in IBD including telemedicine, home biomarker assessment and rapid access clinics. These are some of the novel advancements that have been shown to have great potential at improving Qo C, while offloading some of the burden that IBD can have vis-a-vis emergency room visits and hospital admissions. The aim of the current review is to summarize and discuss available QI sets and recent developments in IBD care including telemedicine, and to give insight into how the utilization of these tools could benefit the Qo C of IBD patients. Additionally, a treating-to-target structure as well as evidence surrounding aggressive management directed at tighter disease control will be presented. | Matthew Strohl Lorant Gonczi Zsuzsanna Kurt Talat Bessissow Peter L Lakatos | 2018 | World Journal of Gastroenterology2018，24，22： | 2 |
| 5 | 利用GRACE重力卫星求解南极洲冰川质量变化的精度研究显示文摘GRACE重力卫星可用于观测南极洲冰川的质量变化。由GRACE重力卫星提供的月解重力场能有效探测质量的年变化及长期变化(周期和非周期性)。通过GRACE观测的质量变化时间序列,计算得到南极洲质量的长期变化及周期性年变化。计算结果受多种误差影响,其中GRACE模型误差的影响较小,而研究时段及其跨度的影响较为显著,以不同宽度的时间窗口进行平移,得到无穷时间序列下该误差的参考值为±14.89mm/a。南极地区的气压修正误差可达±10mm/a,GIA修正误差与其量级相同。由此我们认为,目前对于南极洲冰川质量变化的一些认识仍需商榷。南极洲西部地区冰川加速消融,Dronning Maud Land和Enderby Land等地区的质量持续累积;其他地区的质量变化情况仍需进一步研究。 | Lorant FOLDVARY Annamaria KISS 苏子校 王广才 王林 | 2015 | 地学前缘2015，22，4： | 2 |
| 6 | Reaxff:a reactive force field for hydrocarbons显示文摘 | VAN D A C T DASGUPTA S LORANT F | 2001 | J Phys Chem A2001，105，41： | 1 |
| 7 | Depression and socio-economic risk factors: 7-year longitudinal population study 显示文摘 | Lorant V Croux C Weich S | 2007 | Br J Psychia- try2007，190，： | 1 |
| 8 | Methane genera-tion from methylated aromatics:kinetic study and carbon isotope modeling显示文摘 | Lorant F Behar F Vandenbroucke M | | 0，，： | 1 |
| 9 | Geochemical factors controlling H2S production in petroleum reservoirs during steam injection process:TSR experimental simulation显示文摘 | KowalewskiI Lamoureux-Var V Lorant F | 2005 | Organic Geochemistry Challenges for the 21th Century2005，1，： | 1 |
| 10 | Methane generation from methaylated aromatics: Kinetic study and carbon isotope model ing显示文摘 | Lorant F Behar F Vandenbroucke M | 2000 | Energy &Fuels2000，14，6： | 1 |
| 11 | Functional assessment of the pathogenesis-related protein PR-1b in barley显示文摘 | Holger S Cornelia D Lorant K | | 0，，06： | 1 |
| 12 | Carbon isotopic and mole- cular constraints on the formation and the expulsion of thermo- genic hydrocarbon gases 显示文摘 | Lorant F Prinzhofer A Behar F | 1998 | Chemical Geolo- gy1998，147，34： | 1 |
| 13 | T-cell inhibition does not aggravate bacterial translocation from rat small bowel 显示文摘 | Stenback A Lorant T Meurling S | 2006 | Transpl Immunol2006，16，34： | 1 |
| 14 | Reax F F:a reactive force field for hydrocarbons显示文摘 | van Duin A C T Dasgupta S Lorant F | | 0，，41： | 1 |
| 15 | Carbon isotopic and molecular constraints on the for mation and the expulsion of thermogenic hydrocarbon gases显示文摘 | LORANT F PRINZHOFER A BEHAR F | 1998 | Chemical Geology1998，147，34： | 1 |
| 16 | Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer ceils 显示文摘 | Oh AS Lorant LA Holloway JN | 2001 | Mol Endocrinol2001，15，8： | 1 |
| 17 | Role of NSO compounds during primary cracking of a type Ⅱ kerogen and a type Ⅲ lignite显示文摘 | BEHAR F LORANT F LEWAN M | 2008 | Organic Geochemistry2008，39，1： | 1 |
| 18 | Carbon isotopic and molecular constraints on the formation and the expulsion of thermogenic hydro- carbon gases 显示文摘 | LORANT F PRINZHOFER A BEHAR F | 1998 | Chemical Geology1998，147，： | 1 |
| 19 | A reactive force field for hydrocabons显示文摘 | van Duin ACT Dasgupta S Lorant F | 2001 | Journal of Physical Chemistry A2001，105，： | 1 |
| 20 | Computerized operational control of an electromagnetic wire rope tester显示文摘 | Lorant B Geller K Leung F | 1995 | Mater Eval1995，53，9： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员